Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-α in patients with renal cell carcinoma

Medical Oncology

Volumn 26, Issue 1, 2009, Pages 38-44

  Pavone, L ^a   Fanti, G ^b   Bongiovanni, C ^b   Goldoni, M ^b   Alberici, F ^b   Bonomini, S ^b   Cristinelli, L ^a   Buzio, C ^b  

^a GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Cytotoxicity; Immunological response; Low dose immunotherapy; Natural killer cells; Natural killer T cells

Indexed keywords

CD56 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSGEUSIA; EDEMA; EOSINOPHIL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEARTBURN; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PRURITUS; KIDNEY CARCINOMA; LOW DRUG DOSE; MALAISE; MALE; METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SUBCUTANEOUS NODULE; THYROID DISEASE; TREATMENT OUTCOME; WEIGHT REDUCTION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; MIDDLE AGED; PILOT STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PILOT PROJECTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 65549114691     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9078-7     Document Type: Article

References (31)

1. Coppin C, et al. Immunotherapy for advanced renal cell cancer. In: Cochrane Database of Systematic Reviews, Wiley Publishers; 2008. Issue 2.
2. JC Yang 2003 Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer J Clin Oncol 21 16 3127 32 10.1200/JCO.2003.02.122 (Pubitemid 46606294)
3. DF McDermott 2005 Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 1 133 41 10.1200/JCO.2005.03.206 (Pubitemid 41702632)
4. F Boccardo 1998 Interleukin-2, interferon-α and interleukin-2 plus interferon-α in renal cell carcinoma. A randomized phase II trial Tumori 84 534 9
5. S Negrier 1998 Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 18 1272 8 10.1056/NEJM199804303381805 (Pubitemid 28216581)
6. G Pizzocaro 2001 Interferon adjuvant to radical nephrectomy in Robson Stages II and III Renal Cell Carcinoma: a multicentric randomized study J Clin Oncol 19 2 425 31
7. JI Clark 2003 Adjuvant high dose bolus interleukin-2 for patients with high risk renal cell carcinoma: a cytokine working group randomized trial J Clin Oncol 21 16 3133 40 10.1200/JCO.2003.02.014 (Pubitemid 46606295)
8. J Atzpodien 2005 Adiuvant treatment with interleukin-2 and interferon-alpha 2a based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of prospectively randomised Trial of the German Cooperative Renal Cell Carcinoma Chemoimmunotherapy Group (DGCIN) Br J Cancer 92 843 6 10.1038/sj.bjc.6602443 (Pubitemid 40462628)
9. D Jocham 2004 Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 594 9 10.1016/S0140-6736(04)15590-6 (Pubitemid 38264176)
10. Buzio C, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92(9):2286-96. doi:10.1002/1097-0142(20011101)92: 9<2286::AID-CNCR1575>3.0.CO;2-I (Pubitemid 33029072)
11. L Pavone S Andrulli R Santi M Majori C. Buzio 2001 Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer Cancer Immunol Immunother 50 2 82 6 10.1007/s002620100175 (Pubitemid 32424492)
12. Guinan P, et al. TNM staging of renal cell carcinoma: workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):992-3. doi:10.1002/(SICI)1097-0142(19970901) 80:5<992::AID-CNCR26>3.0.CO;2-Q. (Pubitemid 27360486)
13. C Buzio 1997 Effectiveness of very low doses of immunotherapy in advanced renal cell cancer Br J Cancer 76 4 541 4
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-14. doi:10.1002/1097-0142(19810101)47: 1<207::AID-CNCR2820470134>3.0.CO;2-6. (Pubitemid 11167383)
15. L Chang 1993 Rapid flow cytometric assay for the assessment of natural killer cell activity J Immunol Methods 166 45 54 10.1016/0022-1759(93)90327-4
16. S Johann G Blumel M Lipp R Forster 1995 A versatile flow cytometry-based assay for the determination of short and long-term natural killer cell activity J Immunol Methods 185 209 16 10.1016/0022-1759(95)00116-R
17. MM Nociari A Shalev P Benias P Russo 1998 A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity J Immunol Methods 213 2 157 67 10.1016/S0022-1759(98)00028-3 (Pubitemid 28332808)
18. MA Cooper TA Fehniger MA Caligiuri 2001 The biology of human natural killer-cell subsets Trends Immunol 22 11 633 40 10.1016/S1471-4906(01)02060-9 (Pubitemid 33043908)
19. M Papamichail SA Perez AD Gritzapis CN Baxevanis 2004 Natural killer lymphocytes: biology, development, and function Cancer Immunol Immunother 53 176 86 10.1007/s00262-003-0478-4 (Pubitemid 38328040)
20. P Wersall H Mellstedt 1995 Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and α-IFN Med Oncol 12 69 77 10.1007/BF01676706
21. L Moltò 1999 Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-α-2b and IL-2 J Immunother 22 3 260 7 10.1097/00002371-199905000-00009 (Pubitemid 29226987)
22. F Farace 1995 Low dose IL-2 treatment: activation of discrete T- and NK-cell sub-population in vivo Int J Cancer 62 523 8 10.1002/ijc.2910620506
23. BL Gause 1996 Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer J Clin Oncol 14 8 2234 41
24. W Maxwell 1993 Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma Eur J Surg Oncol 19 3 265 72
25. SB Wilson TL Delovitch 2003 Janus-like role of regulatory NKT cells in autoimmune disease and tumour immunity Nat Rev Immunol 3 211 22 10.1038/nri1028 (Pubitemid 37323206)
26. MT Wilson L Van Kaer 2003 Natural killer T cells as targets for therapeutic intervention in autoimmune diseases Curr Pharm Des 9 201 20 10.2174/1381612033392080 (Pubitemid 36131715)
27. DB Stetson 2003 Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function J Exp Med 198 1069 76 10.1084/jem.20030630 (Pubitemid 37248622)
28. C Karnbach MR Daws EC Niemi MC Nakamura 2001 Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population J Immunol 167 2569 76
29. LS Metelitsa 2001 Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells J Immunol 167 311 422
30. J Swann NY Crowe Y Hayakawa DI Godfrey MJ Smith 2004 Regulation of antitumour immunity by CD1d-restricted NK T cells Immunol Cell Biol 82 323 31 10.1111/j.0818-9641.2004.01254.x
31. SM Tahir 2001 Loss of IFN-gamma production by invariant NK T cells in advanced cancer J Immunol 167 4046 50